3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Endometrial Neoplasms
7
Ovarian Neoplasms
6
Neoplasms
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Neuroendocrine
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Sarcoma, Clear Cell
1
Sarcoma
1
Recurrence
1
Penile Neoplasms
1
Pathologic Complete Response
1
Neoplasms, Second Primary
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
MMRd/MSI-H Stage II-III Endometrial Cancer
1
Interventions
Sunitinib
64
Nivolumab
54
Sorafenib
38
Bevacizumab
35
Axitinib
35
pembrolizumab
34
Everolimus
30
cabozantinib
29
pazopanib
26
aldesleukin
26
Ipilimumab
23
Interleukin-2
19
Specimen Handling
17
Magnetic Resonance Spectroscopy
17
Gemcitabine
17
lenvatinib
16
Interferon-alpha
15
Interferon alpha-2
13
Radiosurgery
12
Cyclophosphamide
12
fludarabine phosphate
11
atezolizumab
10
durvalumab
8
Introns
8
Erlotinib Hydrochloride
8
Biopsy
8
temsirolimus
7
avelumab
7
Radiotherapy
7
Capecitabine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Renal Cell
×
dostarlimab
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled